Nola Hylton

Last updated
Nola Hylton
Born1957 (age 66–67)
Mount Vernon
Alma mater Massachusetts Institute of Technology
Stanford University
Known for Breast MRI
Scientific career
Institutions University of California, San Francisco

Nola M. Hylton (born 1957) is an American oncologist who is Professor of Radiology and Director of the Breast Imaging Research Group at the University of California, San Francisco. She pioneered the usage of magnetic resonance imaging for the detection, diagnosis, and staging of breast cancer by using MRIs to locate tumors and characterize the surrounding tissue.

Contents

Early life and education

Hylton was born in Mount Vernon, New York in 1957. Hylton also studied in Mount Vernon, where she was one of the only Black students in her physics class. [1] Hylton studied chemical engineering at Massachusetts Institute of Technology in 1979. [2] [3] She was an undergraduate fellow at Bell Labs in 1975. She joined Stanford University for her PhD, earning a doctorate in applied physics in 1985, and becoming one of a handful of Black women with doctorates in that period. [1] [4] At Stanford, she worked on analytical techniques to evaluate NMR imaging contrast, which is used in assessing MRIs. [5] She developed hierarchical processing algorithms to characterise the tissues. [6] In her early career she was part of an international trial that compared two breast cancer screening methods, using MRI and mammographies. [7] Hylton was appointed group leader of the working group on Breast MRI systems. [8]

Research and career

Nola Hylton played an integral role in the development of MRI technology for the detection and diagnosis of breast cancer. She was among the first group of scholars named the Susan G. Komen for the Cure’s Scientific Advisory Council and co-leader for the U.S. Department of Health and Human Services’ Women’s Health International Group, where she identified and addressed barriers to clinical dissemination of breast MRI. [9]

Hylton designs MRI biomarkers, which allow her to evaluate how breast cancer responds to treatment. [10] In the 2013 Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And molecular analysis (I-SPY TRIAL), Hylton developed workstations that allow physicians to perform analyses of breast MRI scans. [11] [12] [13] Hylton worked with Hologic to develop software to measure the volume of tumours and analyse images automatically. She expanded the software to include diffusion-weighted imaging (DW-MRI), which helps assess the response of tumours in patients undergoing preoperative chemotherapy. [10] She was principal investigator for ACRIN 6657 and 6698 (I-SPY 2). [14] [15]

She is particularly interested in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). [16] The hologic software DCE-MRI allowed Hylton to monitor breast cancer response in real time. [17] [18] The software was FDA IDE approved in 2010. [17] Hylton demonstrated in 2010 that MRI could be used to predict how women will respond to neoadjuvant therapy. [19] [20] DCE-MRI and DW-MRI provide extra functional information as the MRI becomes sensitive to the vascularity of tumours. [21] Additionally, her recent work has identified that PET and MRI can be used to personalise the treatment of breast cancer. [22]

Hylton served as the principal investigator for the National Cancer Institute's International Breast MRI Consortium. She serves on the University of California, San Francisco Diversity and Inclusion committee. [23]

Selected publications

Awards and honors

Related Research Articles

<span class="mw-page-title-main">Magnetic resonance imaging</span> Medical imaging technique

Magnetic resonance imaging (MRI) is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes inside the body. MRI scanners use strong magnetic fields, magnetic field gradients, and radio waves to generate images of the organs in the body. MRI does not involve X-rays or the use of ionizing radiation, which distinguishes it from computed tomography (CT) and positron emission tomography (PET) scans. MRI is a medical application of nuclear magnetic resonance (NMR) which can also be used for imaging in other NMR applications, such as NMR spectroscopy.

<span class="mw-page-title-main">Prostate biopsy</span>

Prostate biopsy is a procedure in which small hollow needle-core samples are removed from a man's prostate gland to be examined for the presence of prostate cancer. It is typically performed when the result from a PSA blood test is high. It may also be considered advisable after a digital rectal exam (DRE) finds possible abnormality. PSA screening is controversial as PSA may become elevated due to non-cancerous conditions such as benign prostatic hyperplasia (BPH), by infection, or by manipulation of the prostate during surgery or catheterization. Additionally many prostate cancers detected by screening develop so slowly that they would not cause problems during a man's lifetime, making the complications due to treatment unnecessary.

Adjuvant therapy, also known as adjunct therapy, adjuvant care, or augmentation therapy, is a therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments. An example of such adjuvant therapy is the additional treatment usually given after surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant.

MammaPrint is a prognostic and predictive diagnostic test for early stage breast cancer patients that assess the risk that a tumor will metastasize to other parts of the body. It gives a binary result, high-risk or low-risk classification, and helps physicians determine whether or not a patient will benefit from chemotherapy. Women with a low risk result can safely forego chemotherapy without decreasing likelihood of disease free survival. MammaPrint is part of the personalized medicine portfolio marketed by Agendia.

<span class="mw-page-title-main">Breast MRI</span> Form of breast imaging

One alternative to mammography, breast MRI or contrast-enhanced magnetic resonance imaging (MRI), has shown substantial progress in the detection of breast cancer.

Magnetic resonance elastography (MRE) is a form of elastography that specifically leverages MRI to quantify and subsequently map the mechanical properties of soft tissue. First developed and described at Mayo Clinic by Muthupillai et al. in 1995, MRE has emerged as a powerful, non-invasive diagnostic tool, namely as an alternative to biopsy and serum tests for staging liver fibrosis.

Neoadjuvant therapy is the administration of therapeutic agents before a main treatment. One example is neoadjuvant hormone therapy prior to radical radiotherapy for adenocarcinoma of the prostate. Neoadjuvant therapy aims to reduce the size or extent of the cancer before using radical treatment intervention, thus both making procedures easier and more likely to succeed and reducing the consequences of a more extensive treatment technique, which would be required if the tumor were not reduced in size or extent.

<span class="mw-page-title-main">Breast cancer screening</span> Medical screening of asymptomatic, healthy women for breast cancer

Breast cancer screening is the medical screening of asymptomatic, apparently healthy women for breast cancer in an attempt to achieve an earlier diagnosis. The assumption is that early detection will improve outcomes. A number of screening tests have been employed, including clinical and self breast exams, mammography, genetic screening, ultrasound, and magnetic resonance imaging.

PI-RADS is an acronym for Prostate Imaging Reporting and Data System, defining standards of high-quality clinical service for multi-parametric magnetic resonance imaging (mpMRI), including image creation and reporting.

<span class="mw-page-title-main">Breast imaging</span>

In medicine, breast imaging is a sub-speciality of diagnostic radiology that involves imaging of the breasts for screening or diagnostic purposes. There are various methods of breast imaging using a variety of technologies as described in detail below. Traditional screening and diagnostic mammography uses x-ray technology and has been the mainstay of breast imaging for many decades. Breast tomosynthesis is a relatively new digital x-ray mammography technique that produces multiple image slices of the breast similar to, but distinct from, computed tomography (CT). Xeromammography and galactography are somewhat outdated technologies that also use x-ray technology and are now used infrequently in the detection of breast cancer. Breast ultrasound is another technology employed in diagnosis and screening that can help differentiate between fluid filled and solid lesions, an important factor to determine if a lesion may be cancerous. Breast MRI is a technology typically reserved for high-risk patients and patients recently diagnosed with breast cancer. Lastly, scintimammography is used in a subgroup of patients who have abnormal mammograms or whose screening is not reliable on the basis of using traditional mammography or ultrasound.

In the field of medicine, radiomics is a method that extracts a large number of features from medical images using data-characterisation algorithms. These features, termed radiomic features, have the potential to uncover tumoral patterns and characteristics that fail to be appreciated by the naked eye. The hypothesis of radiomics is that the distinctive imaging features between disease forms may be useful for predicting prognosis and therapeutic response for various cancer types, thus providing valuable information for personalized therapy. Radiomics emerged from the medical fields of radiology and oncology and is the most advanced in applications within these fields. However, the technique can be applied to any medical study where a pathological process can be imaged.

Laura Esserman is a surgeon and breast cancer oncology specialist. She is the director of the Carol Franc Buck Breast Care Center at the University of California, San Francisco School of Medicine. She leads the I-SPY trials, Athena Breast Health Network and the WISDOM study. Esserman is an inductee in the Giants of Cancer Care, 2018, for Cancer Diagnostics and the "less is more" approach. She performs live in the show "Audacity" which she co-created. She is also known as the "singing surgeon" for singing to her patients as they go under anesthesia.

<span class="mw-page-title-main">Medical imaging in pregnancy</span> Types of pregnancy imaging techniques

Medical imaging in pregnancy may be indicated because of pregnancy complications, intercurrent diseases or routine prenatal care.

<span class="mw-page-title-main">Daniel Przybysz</span> Brazilian radiation oncologist

Dr. Daniel Przybysz is a Brazilian Radiation-Oncologist. His practice is mainly focused on lung cancer treatment and high technology approaches toward better patient care

The history of magnetic resonance imaging (MRI) includes the work of many researchers who contributed to the discovery of nuclear magnetic resonance (NMR) and described the underlying physics of magnetic resonance imaging, starting early in the twentieth century. One researcher was American physicist Isidor Isaac Rabi who won the Nobel Prize in Physics in 1944 for his discovery of nuclear magnetic resonance, which is used in magnetic resonance imaging. MR imaging was invented by Paul C. Lauterbur who developed a mechanism to encode spatial information into an NMR signal using magnetic field gradients in September 1971; he published the theory behind it in March 1973.

<span class="mw-page-title-main">MRI pulse sequence</span>

An MRI pulse sequence in magnetic resonance imaging (MRI) is a particular setting of pulse sequences and pulsed field gradients, resulting in a particular image appearance.

Denis Le Bihan is a medical doctor, physicist, member of the Institut de France, member of the French Academy of Technologies and director since 2007 of NeuroSpin, an institution of the Atomic Energy and Alternative Energy Commission (CEA) in Saclay, dedicated to the study of the brain by magnetic resonance imaging (MRI) with a very high magnetic field. Denis Le Bihan has received international recognition for his outstanding work, introducing new imaging methods, particularly for the study of the human brain, as evidenced by the many international awards he has received, such as the Gold Medal of the International Society of Magnetic Resonance in Medicine (2001), the coveted Lounsbery Prize, the Louis D. Prize from the Institut de France, the prestigious Honda Prize (2012), the Louis-Jeantet Prize (2014), the Rhein Foundation Award (2021). His work has focused on the introduction, development and application of highly innovative methods, notably diffusion MRI.

Diffuse optical mammography, or simply optical mammography, is an emerging imaging technique that enables the investigation of the breast composition through spectral analysis. It combines in a single non-invasive tool the capability to implement breast cancer risk assessment, lesion characterization, therapy monitoring and prediction of therapy outcome. It is an application of diffuse optics, which studies light propagation in strongly diffusive media, such as biological tissues, working in the red and near-infrared spectral range, between 600 and 1100 nm.

Sylvia Katina Plevritis is Professor and Chair of the Department of Biomedical Data Science at Stanford University.

Pallavi Tiwari is an Indian American biomedical engineer who is a professor at the University of Wisconsin–Madison. Her research considers the development of computer algorithms to accelerate the diagnosis and treatment of disease. She was elected Fellow of the National Academy of Inventors.

References

  1. 1 2 "These Shocking Charts Show How Hard It Is for Black Women in Science". mic.com. Retrieved 2019-02-07.
  2. ↑ "Nola Hylton | UCSF Profiles". profiles.ucsf.edu. Retrieved 2019-02-07.
  3. ↑ "Chemical Engineering Alumni/ae News" (PDF). MIT. Retrieved 2019-02-07.
  4. ↑ Ph.D, Omoviekovwa A. Nakireru (2010-04-19). The Physics Queen: Authorized Biography of Dr. Elvira Louvenia Williams. Xlibris Corporation. ISBN   9781450080965.
  5. ↑ Hylton, N. M.; Ortendahl, D. A.; Kaufman, L.; Crooks, L. E.; Feinberg, D. A. (February 1985). "Analytical Techniques for Post-Imaging Evaluation of NMR Tissue Contrast". IEEE Transactions on Nuclear Science. 32 (1): 803–806. Bibcode:1985ITNS...32..803H. doi:10.1109/TNS.1985.4336944. ISSN   0018-9499. S2CID   41278081.
  6. ↑ Ortendahl, Douglas A.; Hylton, Nola M.; Kaufman, Leon; Crooks, Lawrence E. (1985). "Tissue Characterization Using Intrinsic NMR Parameters and a Hierarchical Processing Algorithm". IEEE Transactions on Nuclear Science. 32 (1): 875–879. Bibcode:1985ITNS...32..875O. doi:10.1109/tns.1985.4336958. ISSN   0018-9499. S2CID   31698229.
  7. ↑ "International Trial Finds Benefits of Breast MRI in Women at High Risk". www.radiologyinfo.org. Retrieved 2019-02-07.
  8. ↑ Hylton, Nola (1999). "Dedicated Breast MRI Systems Working Group Report". Journal of Magnetic Resonance Imaging. 10 (6): 1006–1009. doi:10.1002/(SICI)1522-2586(199912)10:6<1006::AID-JMRI18>3.0.CO;2-5. ISSN   1522-2586. PMID   10581519.
  9. ↑ "13 Black Women in STEM You Should Know!". GoldieBlox. Retrieved 2022-08-31.
  10. 1 2 Newitt, David; Hylton-Watson, Nola. "Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment Trials". Grantome.
  11. ↑ Hylton, Nola M.; Blume, Jeffrey D.; Bernreuter, Wanda K.; Pisano, Etta D.; Rosen, Mark A.; Morris, Elizabeth A.; Weatherall, Paul T.; Lehman, Constance D.; Newstead, Gillian M.; Polin, Sandra; Marques, Helga S.; Esserman, Laura J.; Schnall, Mitchell D.; ACRIN 6657 Trial Team I-SPY 1 TRIAL Investigators (2012). "Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL - Dimensions". Radiology. 263 (3): 663–672. doi:10.1148/radiol.12110748. PMC   3359517 . PMID   22623692 . Retrieved 2019-02-07.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  12. ↑ "The I-SPY Clinical Trials". www.ispytrials.org. Retrieved 2019-02-07.
  13. ↑ "ISPY1 - The Cancer Imaging Archive (TCIA) Public Access - Cancer Imaging Archive Wiki". wiki.cancerimagingarchive.net. Retrieved 2019-02-07.
  14. ↑ Hylton, Nola M.; Blume, Jeffrey D.; Bernreuter, Wanda K.; Pisano, Etta D.; Rosen, Mark A.; Morris, Elizabeth A.; Weatherall, Paul T.; Lehman, Constance D.; Newstead, Gillian M. (June 2012). "Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL". Radiology. 263 (3): 663–672. doi:10.1148/radiol.12110748. ISSN   1527-1315. PMC   3359517 . PMID   22623692.
  15. ↑ Esseman, L.; L'Heureux, D. Z.; Kim, E.; Rosen, M.; Partridge, S. C.; Hylton, N. M. (2011-12-15). "OT2-03-06: ACRIN 6698 MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy: A Sub-Study of the I-SPY 2 TRIAL (Investigation of Serial Studies To Predict Your Therapeutic Response with Imaging And moLecular Analysis)". Cancer Research. 71 (24 Supplement): OT2–03–06–OT2–03–06. doi:10.1158/0008-5472.SABCS11-OT2-03-06. ISSN   0008-5472.
  16. ↑ Hylton, Nola (2006-07-10). "Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker". Journal of Clinical Oncology. 24 (20): 3293–3298. doi:10.1200/JCO.2006.06.8080. ISSN   1527-7755. PMID   16829653.
  17. 1 2 "Nola M. Hylton, PhD | UCSF Helen Diller Family Comprehensive Cancer Center". cancer.ucsf.edu. Retrieved 2019-02-07.
  18. ↑ "Our Calling". UCSF Radiology. Retrieved 2019-02-07.
  19. ↑ Crees, Alex (2015-03-27). "MRI may predict chemotherapy effectiveness early in breast cancer patients". Fox News. Retrieved 2019-02-07.
  20. ↑ "Breast MRI Best at Tracking Response to Chemo: Study". Consumer HealthDay. Retrieved 2019-02-07.
  21. ↑ "Breast Cancer Response to NAC: How Reliable is MRI?" (PDF). ISMRM. Retrieved 2019-02-07.
  22. ↑ "PET and MRI Radiomic Features Can Help Personalize Breast Cancer Diagnosis & Treatment". UCSF Radiology. 2018-10-10. Retrieved 2019-02-07.
  23. ↑ "Commitment to Diversity". UCSF Radiology. 2016-08-09. Retrieved 2019-02-07.
  24. ↑ https://profiles.ucsf.edu/nola.hylton
  25. ↑ "ACRIN 6657" (PDF). ACRIN. Retrieved 2019-02-07.
  26. ↑ ""Ultimate Think Tank" Next Step in Breast Cancer Research from Susan G. Komen for the Cure®". www.businesswire.com. 2010-06-02. Retrieved 2019-02-07.
  27. ↑ "UCSF Radiologists Named Distinguished Investigators of the Academy of Radiology Research!". UCSF Radiology. 2013-07-08. Retrieved 2019-02-07.
  28. ↑ admin (2015-01-31). "2013 Distinguished Investigators Award". The Academy for Radiology & Biomedical Imaging Research. Retrieved 2019-02-07.
  29. ↑ admin. "2017 Fellows of the Society". ISMRM. Retrieved 2019-02-07.
  30. ↑ "Nola Hylton". www.nsbp.org. Retrieved 2019-02-07.
  31. ↑ "Awards and Distinctions". www.sbi-online.org. Retrieved 2019-02-07.
  32. ↑ "Highlights from UCSF Radiology at RSNA 2018". UCSF Radiology. 2018-12-05. Retrieved 2019-02-07.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.